What is the financial performance of Boston Scientific for the first quarter of 2006?

For the first quarter of 2006, Boston Scientific reported net sales of $1,620 million, a slight increase of 0.3% compared to $1,615 million in the prior year. Net income was $332 million, or $0.40 per diluted share, a decrease from $358 million, or $0.42 per diluted share, in the first quarter of 2005. The company adopted new stock-based compensation accounting standards (SFAS 123R), which resulted in a $0.03 per share charge.

What is the significance of the Guidant acquisition mentioned in the filing?

The acquisition of Guidant Corporation, which closed on April 21, 2006 (immediately after the quarter end), is a major transformative event for Boston Scientific. The deal was valued at approximately $27.5 billion and was financed through a combination of cash and company stock. This acquisition is expected to significantly expand BSX's market reach, particularly in the cardiac rhythm management (CRM) business, and diversify its revenue streams.

How did the company finance the Guidant acquisition?

The cash portion of the Guidant acquisition was financed through significant borrowings, including a $5.0 billion term loan and a $700 million interim credit facility, totaling $6.6 billion, along with a $900 million loan from Abbott Laboratories. The company also established a new $2.0 billion revolving credit facility. Additionally, Abbott Laboratories acquired certain Guidant businesses for $4.1 billion cash and provided other financing.

Are there any significant legal proceedings or regulatory issues impacting the company?

Yes, Boston Scientific is involved in numerous legal proceedings, primarily related to patent infringement cases in the coronary stent market, with competitors like Johnson & Johnson and Medtronic. The company also received an FDA warning letter in January 2006 citing regulatory problems at three facilities, indicating potential future regulatory actions if issues are not corrected. The acquisition of Guidant also brought with it Guidant's existing legal and regulatory challenges, including product liability claims and FDA issues related to its CRM devices.

BSX 10-Q Quarterly Report Q1 FY2006 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported its first quarter 2006 financial results, marked by stable net sales growth and a slight decrease in net income compared to the prior year. While overall net sales remained flat at $1,620 million, excluding foreign currency impacts, sales grew by 3%. Net income for the quarter was $332 million, or $0.40 per diluted share, down from $358 million, or $0.42 per diluted share, in Q1 2005. The company adopted new accounting standards for stock-based compensation (SFAS 123R) which impacted results with a $0.03 per share charge. The most significant development during the quarter and immediately following it was the pending and subsequent consummation of the acquisition of Guidant Corporation on April 21, 2006, for approximately $27.5 billion. This transformative deal, which involved both cash and stock, is expected to significantly expand BSX's market presence, particularly in cardiac rhythm management. The company also completed a strategic transaction with Abbott Laboratories, which acquired Guidant's vascular and endovascular businesses. These significant events, including the associated debt financing, will materially impact the company's future financial structure and operations.

Key Highlights

1Net sales for Q1 2006 were $1,620 million, a slight increase of 0.3% compared to $1,615 million in Q1 2005. Excluding foreign currency impacts, net sales grew by 3%.
2Net income for Q1 2006 was $332 million, or $0.40 per diluted share, down from $358 million, or $0.42 per diluted share, in Q1 2005.
3The company adopted SFAS 123(R) 'Share-Based Payment' on January 1, 2006, resulting in stock-based compensation expense impacting net income by $0.03 per diluted share.
4Boston Scientific consummated the acquisition of Guidant Corporation on April 21, 2006, for approximately $27.5 billion (cash and stock), a transaction expected to significantly diversify its business.
5A strategic transaction with Abbott Laboratories involved Abbott acquiring Guidant's vascular intervention and endovascular businesses, and also provided BSX with a loan and access to drug-eluting stent technology.
6Cash provided by operating activities increased to $564 million in Q1 2006 from $441 million in Q1 2005, demonstrating improved cash generation.
7Total assets increased significantly from $8,196 million at December 31, 2005, to $9,109 million at March 31, 2006, largely due to 'Guidant acquisition costs'.

BOSTON SCIENTIFIC CORP Quarterly Report for Q1 Ended Mar 31, 2006

Summary

Key Highlights

Frequently Asked Questions